LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

LAMP Assay Validated for MRSA in Invasive Samples

By LabMedica International staff writers
Posted on 16 Jun 2017
Print article
Image: The eazyplex MRSA test system is designed for the detection of S. aureus and MRSA (pictured) in invasive samples such as pleural and synovial fluid (Photo courtesy of MNT).
Image: The eazyplex MRSA test system is designed for the detection of S. aureus and MRSA (pictured) in invasive samples such as pleural and synovial fluid (Photo courtesy of MNT).
Staphylococcus aureus is a leading cause of bone and joint infections and one of the most common causative pathogens of bacterial pneumonia in children. An increased risk of mortality from invasive staphylococcal infections has been attributed to methicillin-resistant S. aureus (MRSA).

The detection of pathogens by loop-mediated isothermal amplification (LAMP), which is a rapid, cost-effective, and simple method with high sensitivity, has resolved the major limitations of time-consuming culture-based methods and costly polymerase chain reaction (PCR) molecular techniques.

Molecular microbiologists at the University Hospital of Sant Joan de Déu (Barcelona, Spain) evaluated the analytical and diagnostic performance of the eazyplex MRSA test system for the detection of S. aureus and MRSA in invasive samples such as pleural and synovial fluid, in comparison to the gold standard bacterial culture. A volume of spiked pleural sample (analytical validation) or pleural/synovial fluid (diagnostic validation) was diluted in sterile water and genomic DNA was extracted using the NucliSENS EasyMag system.

The team pipetted 25 mL of a DNA mixture were into the six wells of the eazyplex MRSA strip. This contains a reagent mix and six primers in each cap for the simultaneous but individual amplification of Staphylococcus epidermidis- and S. aureus-specific genes, as well as resistance genes mecA and mecC for the detection of MRSA. Amplification products were generated by isothermal autocycling DNA synthesis and visualized by real-time fluorescence measurement with the Genie II device.

The new system appropriately detected a quality control panel of clinical samples with DNA of methicillin-sensitive S. aureus (MSSA), MRSA, and other pathogens. The limit of detection (LoD) was established at 6.4 × 103 CFU/mL for S. aureus and 1.0 × 104 CFU/mL for MRSA. Diagnostic validation of the eazyplex MRSA assay was performed on 51 prospective clinical invasive samples, resulting in sensitivity and specificity values of 83.3% and 97.8%, respectively, for S. aureus detection. The mean turnaround time was 70 minutes.

The authors concluded that the eazyplex MRSA test system was found to have promising potential as a diagnostic tool for the early detection of S. aureus in samples collected from normally sterile body sites. The study was published on in the June 2017 issue of the International Journal of Infectious Diseases.

Related Links:
University Hospital of Sant Joan de Déu

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more